




RealRate

PHARMACEUTICAL 2026

Ionis Pharmaceuticals INC
Rank 119 of 178



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Ionis Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ionis Pharmaceuticals INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 21% points. The greatest weakness of Ionis Pharmaceuticals INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 113% points.

The company's Economic Capital Ratio, given in the ranking table, is 162%, being 68% points below the market average of 229%.

Input Variable	Value in 1000 USD
Assets, Current	2,990,635
Cost of Goods Sold	15,909
Intangible Assets	0
Liabilities, Current	781,567
Liabilities, Non-Current	354,384
Other Assets	410,153
Other Compr. Net Income	5,530
Other Expenses	92,330
Other Liabilities	1,898,796
Other Net Income	92,627
Other Revenues	943,711
Property and Equipment	123,048
Research and Development	915,619
Selling, General and Administrative Expense	393,867

Output Variable	Value in 1000 USD
Assets	3,523,836
Liabilities	3,034,747
Expenses	1,417,725
Revenues	943,711
Stockholders Equity	489,089
Net Income	-381,387
Comprehensive Net Income	-378,622
BaseVar	4,509,088
ECR before LimitedLiability	21%
Economic Capital Ratio	162%